Respiri (ASX:RSH) ticks off significant milestones for wheezo device

" Respiri (ASX:RSH) ticks off significant milestones for wheezo device

Respiri’s (RSH) wheezo device has been given the CE Mark and TGA clearance to be listed in the Australian Therapeutics Goods Register (ARTG).
Zoono (ASX:ZNO) locks in Chinese distribution deal

" Zoono (ASX:ZNO) locks in Chinese distribution deal

Biotech company Zoono’s (ZNO) share price is continuing to rise after announcing it has secured an exclusive Chinese distributor for its product which
Starpharma (ASX:SPL)  progresses to phase 2 DEP cabazitaxel trial

" Starpharma (ASX:SPL) progresses to phase 2 DEP cabazitaxel trial

Starpharma (SPL) has successfully completed the phase 1 component of its phase 1/2 trial for DEP cabazitaxel.
Suda Pharmaceuticals and Sanofi pair up for feasibility study

" Suda Pharmaceuticals and Sanofi pair up for feasibility study

Suda Pharmaceuticals (SUD) and Sanofi-Aventis Groupe have reached an agreement to conduct a feasibility study.
Shares in Creso Pharma falter despite African expansion

" Shares in Creso Pharma falter despite African expansion

Shares in hemp-pharmaceutical company Creso Pharma (CPH) dipped into the red today — despite entering a new market.
Admedus receives 12,500 product order from LeMaitre Vascular

" Admedus receives 12,500 product order from LeMaitre Vascular

LeMaitre Vascular have placed an order for 12,500 units of Admedus’ (AHZ) CardioCel and VascuCel patches for the year ahead.
Botanix receives ethics approval for BTX 1702 in rosacea

" Botanix receives ethics approval for BTX 1702 in rosacea

Botanix Pharmaceuticals (BOT) has received ethics approval for its planned BTX 1702 Phase 1b study for the treatment of rosacea.
1stGroup (ASX:1ST) launches St Vincent software and partnership with Shexie

" 1stGroup (ASX:1ST) launches St Vincent software and partnership with Shexie

It’s been a big day for digital health engine 1stGroup (1ST), with the launch of the company’s St Vincent’s priority referral platform and
Sienna successfully raises $1.7M

" Sienna successfully raises $1.7M

Sienna Cancer Diagnostics (SDX) has raised approximately $1.7 million to accelerate commercialisation of SIEN NET and fund co-development expenditures.
Neuroscientific’s latest Alzheimer’s study brings shares crashing down

" Neuroscientific’s latest Alzheimer’s study brings shares crashing down

Neuroscientific Biopharmaceuticals (NSB) shares have suffered a mighty blow after some underwhelming results from its latest EmtinB study.